Nxera’s partner Cancer Research UK presents a phase 1/2a clinical trial with the cancer immunotherapy drug HTL0039732 on ESMO Page 1

• HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a broad range of cancers in combination with other immunotherapies
• Cancer Research UK’s Centre for Drug Development is sponsoring and managing the ongoing Phase 1/2a clinical trial of HTL0039732

Tokyo, Japan and Cambridge and London, UK, September 13 2024 – Nxera Pharma (TSE: 4565, “Nxera”) and Cancer Research UK announce an upcoming presentation on the ongoing Phase 1/2a clinical trial (NCT05944237) of Nxera’s immunotherapy drug HTL0039732 (also known as NXE0039732) at the European Society for Medical Oncology (ESMO) 2024 Congress, taking place from 13 to 17 September in Barcelona, ​​Spain.

The study’s co-principal investigator, Dr Debashis Sarker from Guy’s and St Thomas’ NHS Foundation Trust, will give a presentation on the ‘research in progress’.¹” poster at ESMO 2024 on Saturday 14 September (presentation 679TiP, available on the ESMO website) here).